The Global Group B Streptococcus (GBS) Diagnosis Market encompasses a wide range of molecular assays, culture-based tests, rapid immunoassays, and point-of-care diagnostic kits designed to detect Streptococcus agalactiae in pregnant women and neonates. These diagnostic products offer high sensitivity, specificity, and quick turnaround times, enabling early intervention and effective antibiotic prophylaxis to reduce the risk of neonatal sepsis and maternal infections. Advances in real-time PCR and next-generation sequencing have improved diagnostic accuracy while reducing sample processing time.

The increasing emphasis on routine prenatal screening guidelines and regulatory approvals has fueled adoption of GBS diagnostic solutions in hospitals, outpatient clinics, and reference laboratories. Moreover, the integration of automated workflows and digital reporting systems enhances laboratory efficiency and data management. As healthcare providers seek better market insights and market growth strategies to address rising Group B Streptococcus (GBS) Diagnosis Market, they are investing in comprehensive testing protocols and quality assurance measures. The availability of multiplex testing platforms also allows simultaneous screening for multiple pathogens, creating additional market opportunities.

The group B streptococcus (GBS) diagnosis market is estimated to be valued at USD 1.67 billion in 2025 and is expected to reach USD 2.45 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.

Key Takeaways
Key players operating in the Group B Streptococcus (GBS) Diagnosis Market are Pfizer Inc., Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc, and Sanofi.

These market players hold significant market share and have established robust product portfolios spanning rapid immunoassays, advanced molecular diagnostics, and prenatal screening kits. Through strategic collaborations, mergers, and targeted research and development initiatives, they continuously refine assay sensitivity and broaden test menus. Their sustained investments in market research and clinical trials reinforce their leadership position, while ongoing regulatory approvals across major markets bolster their competitive edge.

‣ Get more insights on : Group B Streptococcus (GBS) Diagnosis Market

‣ Get this Report in Japanese Language: グループB連鎖球菌GBS診断市場

‣ Get this Report in Korean Language:   그룹B연쇄상구균GBS진단시장